Guselkumab May Have Edge Over Secukinumab in Long-Term Control of Psoriasis

For moderate-to-severe plaque psoriasis, treatment with guselkumab was superior to secukinumab based on 90% or better improvement from baseline in patients' Psoriasis Area and Severity Index score (PASI 90) at 48 weeks in the ECLIPSE study.
Reuters Health Information

Источник

Посмотреть видео: